Showing results (1-10 of 43) with videos related to
Sort By:
Pageof 5
Drugs of Today (Barcelona, Spain : 1998)|December 8, 2011
Ruxolitinib for the treatment of myelofibrosisA Ostojic, R Vrhovac, S VerstovsekCurrent Hematologic Malignancy Reports|August 23, 2014
Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasmsA Yacoub, O Odenike, S VerstovsekCurrent Medicinal Chemistry|July 27, 2012
Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinibJ Mascarenhas, T I Mughal, S VerstovsekLeukemia|May 23, 2017
Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic eraL Falchi, H M Kantarjian, S VerstovsekOncology (Williston Park, N.Y.)|July 11, 2000
CD26 in T-cell lymphomas: a potential clinical role?S Verstovsek, F Cabanillas, N H DangCancer Research|July 15, 1992
Tumoricidal activation of murine resident peritoneal macrophages by interleukin 2 and tumor necrosis factor alphaS Verstovsek, D Maccubbin, M J Ehrke, et al.International Archives of Allergy and Immunology|January 1, 1993
Polymyxin B-mediated lysis of tumor cellsS Verstovsek, D L Maccubbin, M J Ehrke, et al.Molecular Pharmacology|November 1, 1994
Doxorubicin-induced DNA degradation in murine thymocytesG Zaleskis, E Berleth, S Verstovsek, et al.Cancer Immunology, Immunotherapy : CII|June 1, 1995
Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor alpha combination treatment of EL4-lymphoma-bearing C57BL/6 miceC M Krawczyk, S Verstovsek, P Ujházy, et al.Oncology Research|January 1, 1995
Doxorubicin and cyclosporin A affect murine lymphoid cells expressing different antigenic determinantsG Zaleskis, S Verstovsek, T S Tzai, et al.Pageof 5